NO942550L - Humanproteaseinhibitorvariant av Kunitz-type - Google Patents

Humanproteaseinhibitorvariant av Kunitz-type

Info

Publication number
NO942550L
NO942550L NO942550A NO942550A NO942550L NO 942550 L NO942550 L NO 942550L NO 942550 A NO942550 A NO 942550A NO 942550 A NO942550 A NO 942550A NO 942550 L NO942550 L NO 942550L
Authority
NO
Norway
Prior art keywords
amino acid
xaa
naturally occurring
occurring amino
image
Prior art date
Application number
NO942550A
Other languages
English (en)
Norwegian (no)
Other versions
NO942550D0 (no
Inventor
Fanny Norris
Kjeld Norris
Soeren Erik Bjoern
Lars Christian Petersen
Ole Hvilsted Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942550D0 publication Critical patent/NO942550D0/no
Publication of NO942550L publication Critical patent/NO942550L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Saccharide Compounds (AREA)
  • Prostheses (AREA)
  • Amplifiers (AREA)
NO942550A 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type NO942550L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9200001 1992-01-07
PCT/DK1993/000004 WO1993014121A1 (en) 1992-01-07 1993-01-07 A human kunitz-type protease inhibitor variant

Publications (2)

Publication Number Publication Date
NO942550D0 NO942550D0 (no) 1994-07-06
NO942550L true NO942550L (no) 1994-09-07

Family

ID=8153770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942550A NO942550L (no) 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type

Country Status (18)

Country Link
US (1) US5576294A (fi)
EP (1) EP0621871B1 (fi)
JP (1) JP3350549B2 (fi)
KR (1) KR100278036B1 (fi)
AT (1) ATE154938T1 (fi)
AU (1) AU676145B2 (fi)
CA (1) CA2127249A1 (fi)
CZ (1) CZ284911B6 (fi)
DE (1) DE69311893T2 (fi)
ES (1) ES2104121T3 (fi)
FI (1) FI943233A0 (fi)
HU (1) HU218104B (fi)
IL (1) IL104325A (fi)
NO (1) NO942550L (fi)
NZ (1) NZ246569A (fi)
PL (1) PL175422B1 (fi)
WO (1) WO1993014121A1 (fi)
ZA (1) ZA9395B (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE275583T1 (de) * 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
CA2196296C (en) * 1994-08-05 2004-04-06 Michael A. Innis Production of tissue factor pathway inhibitor
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
CA2356404C (en) * 1998-12-22 2010-03-30 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
GB9916913D0 (en) * 1999-07-19 1999-09-22 Natural Enviromental Research Inhibitor proteins
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2386310T (pt) * 2002-08-28 2019-02-05 Dyax Corp Métodos para preservar órgãos e tecidos
DE602004031589D1 (de) * 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CA2536873C (en) * 2003-08-29 2019-09-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
DK2379096T3 (da) 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101798346B (zh) * 2009-02-06 2013-05-29 复旦大学 一种酵母表达的长效重组人组织因子途径抑制物
JP6037841B2 (ja) 2010-01-06 2016-12-07 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
KR101391988B1 (ko) 2011-11-04 2014-05-08 동아대학교 산학협력단 항섬유소용해 기능을 가진 호박벌 독액의 쿠니츠 타입 세린 프로테아제 저해 폴리펩티드 및 이를 코딩하는 염기서열
HUE046572T2 (hu) 2012-03-21 2020-03-30 Baxalta GmbH TFPI inhibitorok és alkalmazási eljárások
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
HUT70295A (en) 1995-09-28
ATE154938T1 (de) 1997-07-15
EP0621871B1 (en) 1997-07-02
CA2127249A1 (en) 1993-07-22
AU3345993A (en) 1993-08-03
US5576294A (en) 1996-11-19
CZ284911B6 (cs) 1999-04-14
DE69311893D1 (de) 1997-08-07
IL104325A0 (en) 1993-05-13
EP0621871A1 (en) 1994-11-02
FI943233A (fi) 1994-07-06
NZ246569A (en) 1996-05-28
HU218104B (hu) 2000-06-28
JPH07506335A (ja) 1995-07-13
ES2104121T3 (es) 1997-10-01
DE69311893T2 (de) 1998-02-05
IL104325A (en) 2000-10-31
FI943233A0 (fi) 1994-07-06
CZ164994A3 (en) 1994-12-15
ZA9395B (en) 1993-08-20
KR940703854A (ko) 1994-12-12
AU676145B2 (en) 1997-03-06
PL175422B1 (pl) 1998-12-31
WO1993014121A1 (en) 1993-07-22
NO942550D0 (no) 1994-07-06
JP3350549B2 (ja) 2002-11-25
KR100278036B1 (ko) 2001-01-15
HU9401991D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
NO942550L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942551L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942549L (no) Humanproteaseinhibitorvariant av Kunitz-type
FI943235A0 (fi) Uusi ihmisen Kunitz-tyyppinen proteaasiestäjä ja sen muunnnoksia
EP0587799A4 (en) CATHEPSIN G AND ELASTASE INHIBITORS PREVENTING DEGRADATION OF CONNECTIVE TISSUE.
CA2043228A1 (en) Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which result from vascular lesions
DE69420145D1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
EP0796867A4 (en) PEPTIDE, BRONCHODILATOR AND AGENT FOR FACILITATING BLOOD FLOW
DE3569541D1 (en) Pharmacologically active peptides
EP1225184A4 (en) HUMAN ANTITHROMBIN VARIANTS
RU97117419A (ru) Эндопротез голеностопного сустава
SE8703855D0 (sv) Vasoaktiva peptider

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application